Increased Confidence in Protein Quantitation: Quantitation of Infliximab in Human Serum with LC-MS/MS for Clinical Research

In this webinar, a sensitive, robust and cost-effective method will be presented for the bioanalysis of IFX with LC–MS/MS by means of a target-based pre-analytical sample purification.

The therapeutic monoclonal antibody, Infliximab (IFX), is a widely used drug for the treatment of several inflammatory autoimmune diseases. However, approximately 10% of patients develop anti-infliximab antibodies (ATIs) rendering the treatment ineffective. Early detection of underexposure to unbound IFX would result in a timely switch of therapy, which could aid in the treatment of this disease.

What will you learn?

• How to develop a confident, robust, reliable, and sensitive quantitation assay for proteins
• Ways to increase efficiency in sample preparation
• The ability to optimize LC and MS methods for performing protein quantitation assays with confidence
• How to address critical challenges in a preclinical environment: from achieving sensitivity to reducing cost/sample

Fill out the form to view the free
on-demand webinar

* Required field